mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 16, Issue 2, Pages 3267-3282
Publisher
MDPI AG
Online
2015-02-03
DOI
10.3390/ijms16023267
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
- (2015) Joan T. Garrett et al. Oncotarget
- Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer
- (2015) Gab-Yong Bae et al. Oncotarget
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience
- (2013) J. C. Yao et al. CANCER RESEARCH
- Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein
- (2013) Ellen Preuss et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer
- (2013) Feng Wei et al. Molecular Cancer
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- (2013) A. C. Faber et al. Cancer Discovery
- Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
- (2012) S. V. Holt et al. CANCER RESEARCH
- Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
- (2012) Hajime Asahina et al. INVESTIGATIONAL NEW DRUGS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
- (2011) Y. Liu et al. MOLECULAR CANCER THERAPEUTICS
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop
- (2011) M. Keniry et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- (2010) Xuerong Wang et al. CANCER BIOLOGY & THERAPY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
- (2009) Yan-Jie Zhang et al. ANNALS OF SURGICAL ONCOLOGY
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
- (2009) Tetsuya Mitsudomi et al. FEBS Journal
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Unravelling the tumor-suppressive functions of FOXO proteins
- (2008) Tobias B. Dansen et al. TRENDS IN CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now